指南与共识头颈与中枢神经肿瘤

成人弥漫性星形细胞和少突胶质细胞肿瘤的治疗:ASCO-SNO指南

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
指南 / 共识 · J Clin Oncol · 2021-12-13

ASCO与神经肿瘤学会召集专家小组系统综述文献,纳入59项随机试验,针对成人弥漫性星形细胞和少突胶质细胞肿瘤的治疗给出推荐,涵盖IDH突变和1p19q共缺失状态及CNS WHO分级对应的放疗、PCV、TMZ、电场治疗等方案。

要点

  • 新诊断少突胶质细胞瘤IDH突变伴1p19q共缺失CNS WHO 2和3级应接受放疗和PCV。
  • 新诊断星形细胞瘤IDH突变伴1p19q非共缺失CNS WHO 2级应接受放疗联合辅助化疗。
  • 新诊断胶质母细胞瘤IDH野生型CNS WHO 4级应接受同步TMZ和放疗后6个月辅助TMZ。

核心结论

  • 针对成人弥漫性星形细胞和少突胶质细胞肿瘤,依据IDH突变、1p19q共缺失状态和CNS WHO分级给出分层治疗推荐。

研究设计与样本

  • ASCO与神经肿瘤学会召集专家小组,对文献进行系统综述,纳入59项聚焦治疗管理的随机试验。

主要发现

  • 共识别59项聚焦治疗管理的随机试验。

关键数值与推荐

  • 新诊断少突胶质细胞瘤IDH突变伴1p19q共缺失CNS WHO 2和3级应接受放疗和PCV;TMZ是不耐受PCV患者的合理替代,但无高级别证据支持 upfront TMZ。
  • 新诊断星形细胞瘤IDH突变伴1p19q非共缺失CNS WHO 2级应接受放疗联合辅助化疗(TMZ或PCV)。
  • 新诊断星形细胞瘤IDH突变伴1p19q非共缺失CNS WHO 3级应接受放疗和辅助TMZ。
  • 星形细胞瘤IDH突变CNS WHO 4级可遵循星形细胞瘤IDH突变伴1p19q非共缺失CNS WHO 3级或胶质母细胞瘤IDH野生型CNS WHO 4级的推荐。
  • 新诊断胶质母细胞瘤IDH野生型CNS WHO 4级应接受同步TMZ和放疗后6个月辅助TMZ;应考虑美国食品药品监督管理局批准的交替电场治疗;不推荐贝伐珠单抗。

临床怎么用

  • 当6周放疗联合TMZ的获益可能不超过 harms 时,大分割放疗联合TMZ是合理的。
  • 年龄≥60至≥70岁、体能状态差或担心毒性或预后的患者,单独最佳支持治疗、单独放疗(MGMT启动子未甲基化肿瘤)或单独TMZ(MGMT启动子甲基化肿瘤)是合理的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. METHODS: ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. RESULTS: Fifty-nine randomized trials focusing on therapeutic management were identified. RECOMMENDATIONS: Adults with newly diagnosed oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, 1p19q codeleted CNS WHO grade 2 and 3 should be offered radiation therapy (RT) and procarbazine, lomustine, and vincristine (PCV). Temozolomide (TMZ) is a reasonable alternative for patients who may not tolerate PCV, but no high-level evidence supports upfront TMZ in this setting. People with newly diagnosed astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 2 should be offered RT with adjuvant chemotherapy (TMZ or PCV). People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT and adjuvant TMZ. People with astrocytoma, IDH-mutant, CNS WHO grade 4 may follow recommendations for either astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 or glioblastoma, IDH-wildtype, CNS WHO grade 4. Concurrent TMZ and RT should be offered to patients with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 followed by 6 months of adjuvant TMZ. Alternating electric field therapy, approved by the US Food and Drug Administration, should be considered for these patients. Bevacizumab is not recommended. In situations in which the benefits of 6-week RT plus TMZ may not outweigh the harms, hypofractionated RT plus TMZ is reasonable. In patients age ≥ 60 to ≥ 70 years, with poor performance status or for whom toxicity or prognosis are concerns, best supportive care alone, RT alone (for MGMT promoter unmethylated tumors), or TMZ alone (for MGMT promoter methylated tumors) are reasonable treatment options. Additional information is available at www.asco.org/neurooncology-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mohile NA, Messersmith H, Gatson NT, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol. 2021. PMID: 34898238. doi:10.1200/JCO.21.02036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。